Great Hill Partners plans to acquire an approximately 44% stake in specialty infusion pharmacy provider AvevoRx, Healthcare Dealflow is the first to report. Neither company has announced the transaction.
Healthcare Dealflow identified the pending investment through a Notice of Material Change filed with the Massachusetts Health Policy Commission. Under a Membership Interests Purchase Agreement signed September 28, Encore AV Blocker, Inc., an affiliate of Great Hill formed for the transaction, will acquire approximately 44% of AvevoRx’s outstanding membership interests.
The filing does not identify the selling shareholders or disclose a purchase price.
Stay Informed
The Daily Brief covers healthcare M&A deal activity, news, and trends every business day.
Join the investment banks, private equity firms, and advisors who rely on it to stay current.
Subscribe to The Daily Brief →Greensboro, North Carolina-based AvevoRx and its subsidiaries operate specialty infusion pharmacies and provide infusion care services across the U.S. Although the company does not have any locations in Massachusetts, it serves patients in the state and holds Massachusetts pharmacy licenses through AvevoRx and subsidiary Access to Care, LLC.
Great Hill is a Boston-based private equity firm focused on growth investments in middle-market companies across sectors including healthcare technology, software, fintech and business and consumer services.
The transaction will leave AvevoRx as the same operating entity, with no anticipated changes to its operations, licenses, locations or taxpayer identification number. According to the filing, Great Hill’s investment is intended to provide additional capital and resources to support growth in AvevoRx’s specialty infusion pharmacy business.
The companies do not expect the transaction to result in changes to reimbursement rates, referral patterns, access to services or quality of care.
The proposed effective date is December 28, 2026, or upon receipt of regulatory approvals, with closing expected in the fourth quarter. The parties submitted notice of the transaction to the Indiana Attorney General on October 2 and also expect to make customary filings with state boards of pharmacy and Medicare and Medicaid programs.
The investment comes amid continued private equity and strategic activity in specialty infusion. Earlier this month, CD&R and McKesson agreed to acquire Option Care Health at an enterprise value of approximately $5.8 billion, with CD&R expected to own roughly 51% of the company and McKesson the remainder.
Other transactions this year have included SkyKnight Capital’s partnership with Apex Infusion Partners and Nautic Partners’ growth investment in KabaFusion. Healthcare Dealflow also recently reported AOM’s planned acquisition of PromptCare Infusion.
Healthcare Dealflow is a healthcare M&A intelligence platform that tracks deal activity, trends and analysis across the healthcare sector for an audience of private equity firms, investment banks, corporate development teams, and transaction advisors. Subscribe to The Daily Brief here.